AstraZeneca Pharma India Limited (506820) Fair Value & Analysis
Healthcare · IN · Market cap ₹108B
Fair value as of: Aug 15, 2026
From 26 valuation models · updated 3 days ago
Share price −4.5% over the past month.
A solid business, but screening 89% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (₹1,010). The favourable scenario is already priced in.
- Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (₹478.38 to ₹1,010) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 15, 2026.
How to read this chart
60‑month range ₹2,409 – ₹10,442 · fair‑value band ₹478.38 – ₹1,010 · the ₹7,629 price screens above the ₹810.13 fair value. Dashed = 300-day average. As of Aug 15, 2026.
Analysis
AstraZeneca Pharma India Limited (506820) currently trades at ₹7,629, while our model-based Fair Value estimate is ₹810.13, implying the stock looks roughly 89.4% overvalued today. The Quality Score stands at 57/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, AstraZeneca Pharma India Limited generated revenue of ₹8.2B at a net margin of 9.9%. Revenue grew 0.5% year over year. It earns a return on equity of 22.1%. The stock trades on a trailing P/E of 154.2 (as of Aug 15, 2026). Fundamentals as of Aug 15, 2026
Our scenario range runs from ₹478.38 (bear case) to ₹1,010 (bull case); at ₹7,629, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 22% below its 52-week high. For context, the median of 10 Healthcare peers we cover trades at -36% fair-value upside, at -89%, 506820 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (₹1,255) versus Asset-Based (₹206.45). Highest evidence: Residual Income (76).
Notify me when 506820 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 15, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 57 · Market factors (momentum, volatility) 42
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and distributes pharmaceutical products in India and internationally. It manufactures and sells medicines under the Brilinta, Axcer, Forxiga, Oxra, Gledepa, Xigduo, Symbicort, Onglyza, Kombiglyze, Tagrisso, Lynparza, Zoladex, QTERN, and Imfinzi brand names.
Full company description
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and distributes pharmaceutical products in India and internationally. It manufactures and sells medicines under the Brilinta, Axcer, Forxiga, Oxra, Gledepa, Xigduo, Symbicort, Onglyza, Kombiglyze, Tagrisso, Lynparza, Zoladex, QTERN, and Imfinzi brand names. The company offers products in the areas of cardiovascular, renal, metabolic, oncology, antidiabetic, respiratory, inflammation, and autoimmunity diseases. It also provides clinical trial services. The company was founded in 1979 and is headquartered in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
AstraZeneca Pharma India Limited reported revenue of ₹17.2B in FY2025 versus ₹8.1B in FY2021, a compound +20.5%/yr. Reported net income was ₹1.2B in FY2025, compounding +5.5%/yr from FY2021.
506820 screens 89% overvalued. Compare with Granules India Limited →
Peer Group
Health Care · 2250 stocks
How this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Drug Manufacturers - Major” was too small, so the broader sector is used.)
Valuation Multiples vs Health Care median · lower = cheaper
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Major stocks, each showing price versus our Fair Value estimate (as of Aug 15, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Granules India Limited 532482 | ₹861.80 | ₹420.24 | -51% |
| FDC Limited 531599 | ₹354.40 | ₹255.06 | -28% |
| Marksans Pharma Limited 524404 | ₹331.65 | ₹151.74 | -54% |
| Bliss GVS Pharma Limited 506197 | ₹524.05 | ₹104.64 | -80% |
| Lincoln Pharmaceuticals Limited 531633 | ₹612.85 | ₹600.51 | -2% |
| Albert David Limited 524075 | ₹808.85 | ₹500.79 | -38% |
| Syncom Formulations (India) Limited 524470 | ₹15.88 | ₹10.20 | -36% |
| Wanbury Limited 524212 | ₹250.55 | ₹226.69 | -10% |
| Makers Laboratories Limited 506919 | ₹153.20 | ₹105.20 | -31% |
| Syschem (India) Limited 531173 | ₹30.91 | ₹7.53 | -76% |
Compare AstraZeneca Pharma India Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is AstraZeneca Pharma India Limited (506820) overvalued or undervalued?
What is the fair value of 506820?
What is the quality score of 506820?
What is the revenue of AstraZeneca Pharma India Limited (506820)?
What is the net profit margin of 506820?
Does AstraZeneca Pharma India Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track AstraZeneca Pharma India Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.